263 related articles for article (PubMed ID: 35920788)
1. JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Gillard L; Pouchot J; Cohen-Aubart F; Koné-Paut I; Mouterde G; Michaud M; Reumaux H; Savey L; Belot A; Fautrel B; Mitrovic S
Rheumatology (Oxford); 2023 Apr; 62(4):1594-1604. PubMed ID: 35920788
[TBL] [Abstract][Full Text] [Related]
2. Anakinra in children and adults with Still's disease.
Vastert SJ; Jamilloux Y; Quartier P; Ohlman S; Osterling Koskinen L; Kullenberg T; Franck-Larsson K; Fautrel B; de Benedetti F
Rheumatology (Oxford); 2019 Nov; 58(Suppl 6):vi9-vi22. PubMed ID: 31769856
[TBL] [Abstract][Full Text] [Related]
3. [Anakinra in refractory adult onset Still's disease].
Vercoutere W; Starmans-Kool M; Peeters RM
Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study.
Laskari K; Tzioufas AG; Moutsopoulos HM
Arthritis Res Ther; 2011 Jun; 13(3):R91. PubMed ID: 21682863
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
6. Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.
Colafrancesco S; Manara M; Bortoluzzi A; Serban T; Bianchi G; Cantarini L; Ciccia F; Dagna L; Govoni M; Montecucco C; Priori R; Ravelli A; Sfriso P; Sinigaglia L;
Arthritis Res Ther; 2019 Dec; 21(1):275. PubMed ID: 31829244
[TBL] [Abstract][Full Text] [Related]
7. Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies.
Efthimiou P; Kontzias A; Hur P; Rodha K; Ramakrishna GS; Nakasato P
Semin Arthritis Rheum; 2021 Aug; 51(4):858-874. PubMed ID: 34175791
[TBL] [Abstract][Full Text] [Related]
8. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy.
Giampietro C; Ridene M; Lequerre T; Costedoat Chalumeau N; Amoura Z; Sellam J; Sibilia J; Bourgeois P; Fautrel B;
Arthritis Care Res (Hoboken); 2013 May; 65(5):822-6. PubMed ID: 23225779
[TBL] [Abstract][Full Text] [Related]
9. Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy.
Vercruysse F; Barnetche T; Lazaro E; Shipley E; Lifermann F; Balageas A; Delbrel X; Fautrel B; Richez C; Schaeverbeke T; Truchetet ME
Arthritis Res Ther; 2019 Feb; 21(1):53. PubMed ID: 30755262
[TBL] [Abstract][Full Text] [Related]
10. The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry.
Ruscitti P; Sota J; Vitale A; Lopalco G; Iannone F; Morrone M; Giardini HAM; D'Agostin MA; Antonelli IPB; Almaghlouth I; Asfina KN; Khalil N; Sfikakis PP; Laskari K; Tektonidou M; Ciccia F; Iacono D; Riccio F; Ragab G; Hussein MA; Govoni M; Ruffilli F; Direskeneli H; Alibaz-Oner F; Giacomelli R; Navarini L; Bartoloni E; Riccucci I; Martín-Nares E; Torres-Ruiz J; Cipriani P; Di Cola I; Hernández-Rodríguez J; Gómez-Caverzaschi V; Dagna L; Tomelleri A; Makowska J; Brzezinska O; Iagnocco A; Bellis E; Caggiano V; Gaggiano C; Tarsia M; Mormile I; Emmi G; Sfriso P; Monti S; Erten Ş; Del Giudice E; Lubrano R; Conti G; Olivieri AN; Lo Gullo A; Tharwat S; Karamanakos A; Gidaro A; Maggio MC; La Torre F; Cardinale F; Ogunjimi B; Maier A; Sebastiani GD; Opris-Belinski D; Frassi M; Viapiana O; Bizzi E; Carubbi F; Fotis L; Tufan A; Kardas RC; Więsik-Szewczyk E; Jahnz-Różyk K; Fabiani C; Frediani B; Balistreri A; Rigante D; Cantarini L
Semin Arthritis Rheum; 2023 Oct; 62():152244. PubMed ID: 37517110
[TBL] [Abstract][Full Text] [Related]
11. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Kalliolias GD; Liossis SN
Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
[TBL] [Abstract][Full Text] [Related]
12. Cytokine profile in adult-onset Still's disease: Comparison with systemic juvenile idiopathic arthritis.
Inoue N; Shimizu M; Tsunoda S; Kawano M; Matsumura M; Yachie A
Clin Immunol; 2016 Aug; 169():8-13. PubMed ID: 27263804
[TBL] [Abstract][Full Text] [Related]
13. Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease.
Ruscitti P; Natoli V; Consolaro A; Caorsi R; Rosina S; Giancane G; Naddei R; Di Cola I; Di Muzio C; Berardicurti O; Iacono D; Pantano I; Rozza G; Rossi S; De Stefano L; Balduzzi S; Vitale A; Caso F; Costa L; Prete M; Navarini L; Iagnocco A; Atzeni F; Guggino G; Perosa F; Cantarini L; Frediani B; Montecucco C; Ciccia F; Cipriani P; Gattorno M; Giacomelli R; Ravelli A
Rheumatology (Oxford); 2022 Oct; 61(10):4124-4129. PubMed ID: 35078234
[TBL] [Abstract][Full Text] [Related]
14. The latest advances in the use of biological DMARDs to treat Still's disease.
Di Cola I; Ruscitti P
Expert Opin Biol Ther; 2024; 24(1-2):63-75. PubMed ID: 38284774
[TBL] [Abstract][Full Text] [Related]
15. Canakinumab for the treatment of adult-onset Still's disease.
Sfriso P; Bindoli S; Doria A; Feist E; Galozzi P
Expert Rev Clin Immunol; 2020 Feb; 16(2):129-138. PubMed ID: 31957508
[No Abstract] [Full Text] [Related]
16. Successful outcome of two pregnancies in patients with adult-onset Still's disease treated with IL-1 receptor antagonist (anakinra).
Fischer-Betz R; Specker C; Schneider M
Clin Exp Rheumatol; 2011; 29(6):1021-3. PubMed ID: 22153586
[TBL] [Abstract][Full Text] [Related]
17. Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease.
Vitale A; Berlengiero V; Sota J; Ciarcia L; Ricco N; Barneschi S; Mourabi M; Lopalco G; Marzo C; Bellisai F; Iannone F; Frediani B; Cantarini L
Mediators Inflamm; 2020; 2020():8054961. PubMed ID: 33122969
[TBL] [Abstract][Full Text] [Related]
18. Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort.
Ruscitti P; Cipriani P; Liakouli V; Iacono D; Pantano I; Caso F; Perosa F; Atzeni F; Cantatore FP; Scarpa R; Ciccia F; Giacomelli R
Rheumatol Int; 2020 Jan; 40(1):107-113. PubMed ID: 31263993
[TBL] [Abstract][Full Text] [Related]
19. Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still's disease.
Tamaki H; Shimizu H; Hiraoka E; Uechi E; Kishimoto M; Yamaguchi K; Okada M
Mod Rheumatol; 2010 Apr; 20(2):200-4. PubMed ID: 20037747
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of canakinumab in the treatment of adult-onset Still's disease: A systematic review.
Cota-Arce JM; Cota J; De León-Nava MA; Hernández-Cáceres A; Moncayo-Salazar LI; Valle-Alvarado F; Cordero-Moreno VL; Bonfil-Solis KL; Bichara-Figueroa JE; Hernández-Hernández J; Villela L
Semin Arthritis Rheum; 2021 Dec; 51(6):1282-1290. PubMed ID: 34493394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
